Precision Therapeutics in NF1 Associated Tumors

CE / CME

Precision Therapeutics for NF1-Associated Tumors: Improved Outcomes Through Targeted MEK Inhibition

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: December 24, 2024

Expiration: June 23, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How confident are you in your ability to incorporate MEK inhibitors into treatment plans for patients with NF1-associated plexiform neurofibromas based on the latest evidence, recommendations, and individual patient and tumor characteristics?

2.

In a recent phase IIb trial, which of the following MEK inhibitors showed activity in both pediatric and adult patients with NF1-associated plexiform neurofibromas when administered as either a capsule or an oral suspension?

3.

In addition to supportive care, what would you recommend if an adolescent patient develops grade 2 skin toxicities on treatment with selumetinib?